Loading
A phase 1/2 trial of XZP-5955 tablets in non-small-cell lung cancer, run by Xuanzhu Biopharmaceutical Co., Ltd., now recruiting.
A Study of XZP-5955 Tablets in Patients With NTRK or ROS1 Fusion Positive Locally Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04996121 by Xuanzhu Biopharmaceutical Co., Ltd., with 360 participants planned, started 2021-12-06 and due to reach its primary completion in 2025-09. Interventions recorded: XZP-5955 tablets.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Xuanzhu Biopharmaceutical and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Shares Xuanzhu Biopharmaceutical and the tag pipeline.
Shares NTRK fusion-positive non-small-cell lung cancer, ROS1-positive non-small-cell lung cancer and the tag pipeline.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/